5月21日，德康医疗盘中上涨5.01%，报70.305美元/股，成交额3.62亿美元。
消息面上，公司近期多重利好持续发酵。此前德康医疗宣布与知名激进投资机构艾略特投资管理达成合作协议，共同引入两位新独立董事并扩大运营与创新委员会职权范围，全面监督运营、质量管理及技术路线图，市场将此视为治理优化的积极信号。同时，公司在投资者日发布新长期财务目标，预计至2030年有机收入年增速超10%，并设定非GAAP毛利率67%-69%、营业利润率29%-30%的目标。此外，董事会批准了高达10亿美元的股票回购计划。产品端，公司在德国推出面向2型糖尿病的Dexcom Flex连续血糖监测系统，进一步拓展市场覆盖。此前该股52周内跌幅逾30%，多重催化剂叠加下市场修复预期持续升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.